Skip to main content

Table 2 Univariable and multivariable cox analysis of OS before propensity matched analysis

From: Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis

Variable Univariable Multivariable
HR 95% CI P HR 95% CI P
Age (≥60/< 60, year) 1.279 0.857–1.908 0.229
Sex (Men/Women) 1.443 0.95–2.193 0.085
HBsAg (yes/no) 1.044 0.719–1.517 0.821
HCV antibody (yes/no) 2.293 0.722–7.283 0.159
AFP (≥20/< 20, ng/mL) 2.819 0.68–11.682 0.153
CEA (≥5/<5, ng/mL) 1.844 0.643–5.29 0.255
CA19–9 (≥37/<37, U/mL) 2.069 0.639–6.702 0.225
Liver cirrhosis, yes (%) 1.252 0.857–1.83 0.245
TB (≥17/< 17, μmol/L) 0.950 0.626–1.443 0.810
ALB (≥40/<40, g/mL) 0.759 0.530–1.086 0.132
ALT (≥35/<35, U/L) 1.327 0.941–1.870 0.106
γ-GT (≥40/<40, U/L) 2.662 1.703–4.163 < 0.001 2.152 1.354–3.421 0.001
PLT (≥10/< 10 103/μL) 1.005 0.665–1.518 0.982
Prothrombin time, median (range), s 1.199 0.781–1.841 0.406
Tumour size, cm 1.769 1.235–2.534 0.002 1.274 0.867–1.872 0.218
Tumour nodularities 1.167 1.055–1.292 0.003 1.130 1.011–1.262 0.031
Occlusion, min (< 20/≥20) 0.290 0.740–2.250 0.369
Macrovascular invasion (yes/no) 1.927 1.442–2.576 < 0.001 1.869 1.375–2.540 < 0.001
Microvascular invasion (yes/no) 1.365 0.921–2.204 0.122
Lymphoid metastasis (yes/no) 2.801 1.745–4.495 < 0.001 2.031 1.201–3.435 0.008
Extrahepatic metastasis (yes/no) 11.435 5.262–24.849 < 0.001 6.392 2.731–14.961 < 0.001
Preventive TACE (yes/no) 1.212 0.807–1.821 0.354
  1. HBsAg hepatitis B surface antigen, HCV hepatitis C virus, AFP α-fetoprotein, CEA carcino-embryonic antigen, CA19–9 carbohydrate 19–9, TB total bilirubin, ALB albumin, ALT alanine aminotransferase, γ-GT γ-glutamyl transpeptidase, PLT platelet, ALP alkaline phosphatase
\